Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kveiborg, Marie
Albrechtsen, Reidar
Couchman, John R.
and
Wewer, Ulla M.
2008.
Cellular roles of ADAM12 in health and disease.
The International Journal of Biochemistry & Cell Biology,
Vol. 40,
Issue. 9,
p.
1685.
Howard, Beatrice A.
2008.
The Role of NRG3 in Mammary Development.
Journal of Mammary Gland Biology and Neoplasia,
Vol. 13,
Issue. 2,
p.
195.
Wansbury, Olivia
Panchal, Heena
James, Michelle
Parry, Suzanne
Ashworth, Alan
and
Howard, Beatrice
2008.
Dynamic Expression of Erbb Pathway Members during Early Mammary Gland Morphogenesis.
Journal of Investigative Dermatology,
Vol. 128,
Issue. 4,
p.
1009.
Frogne, Thomas
Benjaminsen, Rikke V.
Sonne-Hansen, Katrine
Sorensen, Boe S.
Nexo, Ebba
Laenkholm, Anne-Vibeke
Rasmussen, Louise M.
Riese, David J.
de Cremoux, Patricia
Stenvang, Jan
and
Lykkesfeldt, Anne E.
2009.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Breast Cancer Research and Treatment,
Vol. 114,
Issue. 2,
Pedersen, Nina Marie
Breen, Kamilla
Rødland, Marianne Skeie
Haslekås, Camilla
Stang, Espen
and
Madshus, Inger Helene
2009.
Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2.
Molecular Cancer Research,
Vol. 7,
Issue. 2,
p.
275.
Watt, Heather L.
Kharmate, Geetanjali D.
and
Kumar, Ujendra
2009.
Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: Agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.
Cellular Signalling,
Vol. 21,
Issue. 3,
p.
428.
Zahnow, Cynthia A.
2009.
CCAAT/enhancer-binding protein β: its role in breast cancer and associations with receptor tyrosine kinases.
Expert Reviews in Molecular Medicine,
Vol. 11,
Issue. ,
Zhang, Li
Guo, Weixiang
Chen, Qi
Fan, Xiujun
Zhang, Ying
and
Duan, Enkui
2009.
Adam12 plays a role during uterine decidualization in mice.
Cell and Tissue Research,
Vol. 338,
Issue. 3,
p.
413.
Capri, G.
Chang, J.
Chen, S.-C.
Conte, P.
Cwiertka, K.
Jerusalem, G.
Jiang, Z.
Johnston, S.
Kaufman, B.
Link, J.
Ro, J.
Schütte, J.
Oliva, C.
Parikh, R.
Preston, A.
Rosenlund, J.
Selzer, M.
Zembryki, D.
and
De Placido, S.
2010.
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Annals of Oncology,
Vol. 21,
Issue. 3,
p.
474.
Glück, Stefan
Arteaga, Carlos L.
and
Osborne, C. Kent
2011.
Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient.
Clinical Cancer Research,
Vol. 17,
Issue. 17,
p.
5559.
Ito, Tokiko
Kamijo, Shinobu
Izumi, Hiroto
Kohno, Kimitoshi
Amano, Jun
and
Ito, Ken-ichi
2012.
Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Breast Cancer Research and Treatment,
Vol. 133,
Issue. 1,
p.
145.
Sak, Malgorzata Magdalena
Breen, Kamilla
Rønning, Sissel Beate
Pedersen, Nina Marie
Bertelsen, Vibeke
Stang, Espen
and
Madshus, Inger Helene
2012.
The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.
Carcinogenesis,
Vol. 33,
Issue. 5,
p.
1031.
Larsen, Mathilde S.
Bjerre, Karsten
Lykkesfeldt, Anne E.
Giobbie-Hurder, Anita
Lænkholm, Anne-Vibeke
Henriksen, Katrine L.
Ejlertsen, Bent
and
Rasmussen, Birgitte B.
2012.
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
The Breast,
Vol. 21,
Issue. 5,
p.
662.
Blackwell, Kimberly L.
Burstein, Harold J.
Storniolo, Anna Maria
Rugo, Hope S.
Sledge, George
Aktan, Gursel
Ellis, Catherine
Florance, Allison
Vukelja, Svetislava
Bischoff, Joachim
Baselga, José
and
O'Shaughnessy, Joyce
2012.
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study.
Journal of Clinical Oncology,
Vol. 30,
Issue. 21,
p.
2585.
Schalper, Kurt A.
Riquelme, Manuel A.
Brañes, María C.
Martínez, Agustín D.
Vega, José Luis
Berthoud, Viviana M.
Bennett, Michael V. L.
and
Sáez, Juan C.
2012.
Modulation of gap junction channels and hemichannels by growth factors.
Molecular BioSystems,
Vol. 8,
Issue. 3,
p.
685.
Fhayli, Wassim
Ghandour, Zeinab
Mariko, Boubacar
Pezet, Mylène
and
Faury, Gilles
2012.
Rôle de l'élastine et des microfibrilles de la paroi artérielle au cours du développement et du vieillissement : complémentarité ou opposition ?.
Biologie Aujourd'hui,
Vol. 206,
Issue. 2,
p.
87.
Guan, Zhongzhen
Xu, Binghe
DeSilvio, Michelle L.
Shen, Zhenzhou
Arpornwirat, Wichit
Tong, Zhongsheng
Lorvidhaya, Vicharn
Jiang, Zefei
Yang, Junlan
Makhson, Anatoly
Leung, Wai Lim
Russo, Mark W.
Newstat, Beth
Wang, Li
Chen, George
Oliva, Cristina
and
Gomez, Henry
2013.
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer.
Journal of Clinical Oncology,
Vol. 31,
Issue. 16,
p.
1947.
Giordano, Sara B
and
Kaklamani, Virginia
2013.
Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2.
Breast Cancer Management,
Vol. 2,
Issue. 6,
p.
529.
Kirkegaard, Tove
Hansen, Susanne K.
Larsen, Sarah L.
Reiter, Birgit E.
Sørensen, Boe S.
and
Lykkesfeldt, Anne E.
2014.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Cancer Letters,
Vol. 344,
Issue. 1,
p.
90.
KIRKEGAARD, TOVE
YDE, CHRISTINA W.
KVEIBORG, MARIE
and
LYKKESFELDT, ANNE E.
2014.
The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
International Journal of Oncology,
Vol. 45,
Issue. 1,
p.
393.